Physician profile
John W Moore
NPI 1669552550
$2,202.36
in general payments reported to CMS, 2019-2025
13 companies · $851 in 2025
The $851 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $445 · 2022: $293 · 2023: $409 · 2024: $205 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $804.36 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $284.42 | 2021-2025 | Nucala, Trelegy Ellipta |
| Lilly USA, LLC | $194.63 | 2022-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $183.07 | 2021-2025 | |
| Bridgebio Pharma, INC. | $182.78 | 2025 | Attruby |
| Insulet Corporation | $150.00 | 2025 | Omnipod |
| Novo Nordisk INC | $137.37 | 2022-2025 | Wegovy |
| Amgen INC. | $135.00 | 2025 | Evenity |
| Nestle Healthcare Nutrition INC. | $54.78 | 2021-2022 | |
| Corcept Therapeutics | $31.45 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.71 | 2025 | Xifaxan |
| Electromed, INC. | $14.84 | 2025 | Smartvest |
| Genentech USA, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.